Inmune Bio CFO acquires $49k in company stock

In a recent transaction, David J. Moss, the Chief Financial Officer of Inmune Bio, Inc. (NASDAQ:INMB ), a company specializing in biological products, has increased his stake in the company. On September 12, 2024, Moss purchased 7,690 shares of Inmune Bio's common stock at a price of $6.375 per share, amounting to a total investment of $49,023.


This purchase demonstrates a strong vote of confidence from Moss in the future of Inmune Bio. Following the transaction, the CFO now holds a total of 1,275,869 shares of the company's common stock directly. The acquisition aligns with the company's ongoing efforts to advance its position in the biological products sector.


Additionally, Moss also acquired the same number of common stock warrants, which grant him the right to purchase additional shares at a future date. The warrants have an exercise price of $6.40 each and are exercisable starting March 16, 2025, with an expiration date of March 16, 2030. The terms of the warrants include provisions for an extended exercise period in certain circumstances related to insider trading blackouts.


The transactions were part of a registered direct offering, as per the footnotes in the SEC filing, with an aggregate purchase price of $13,000,000 for the combined shares and warrants. This strategic move by Moss may indicate his expectation of potential growth or a favorable outlook for Inmune Bio, as the acquisition of both stock and warrants suggests a long-term commitment to the company's success.


Investors often monitor insider transactions such as these for insights into how the company's executives view the stock's valuation and prospects. Moss's recent investments have certainly provided such insights, showing a reinforcing belief in the company's direction and potential.



In other recent news, INmune Bio Inc. has generated approximately $13 million in gross proceeds from a registered direct offering of common stock and corresponding warrants, involving both new and existing institutional investors as well as company insiders. The anticipated closing date for the offering is around September 16, 2024, subject to customary closing conditions. Proceeds are intended for working capital and general corporate purposes, with A.G.P./Alliance Global Partners (NYSE:GLP ) serving as the sole placement agent.


Additionally, Scotiabank initiated coverage on shares of INmune Bio with a Sector Outperform rating, underlining the potential of the company's lead drug candidate, XPro, currently in clinical development for the treatment of Alzheimer's disease. The company is expected to release top-line results from a six-month Phase 2 trial of XPro in early Alzheimer's patients in the second quarter of 2025.


Furthermore, INmune Bio reported significant progress in its INKmune memory-like natural killer cell oncology platform and its ongoing Phase II Alzheimer's study during its second quarter 2024 earnings call. The interim analysis of the Phase II trial of XPro in early Alzheimer's disease showed promising results, and the company raised approximately $14.5 million in gross proceeds from equity offerings, ensuring sufficient funds for operations until 2025. These recent developments underline INmune Bio's commitment to advancing its clinical trials and bringing innovative treatments to the market.
InvestingPro Insights


As Inmune Bio's CFO David J. Moss increases his stake in the company, investors are keen to understand the financial health and market performance of Inmune Bio, Inc. (NASDAQ:INMB). According to InvestingPro data, Inmune Bio currently holds a market capitalization of $105.72 million. The company's stock has been experiencing significant volatility, with a price that has recently dipped to near its 52-week low, reflecting a potential area of interest for value investors.


The financial metrics reveal a challenging picture, with the company not being profitable over the last twelve months and analysts expecting both a sales decline and a drop in net income in the current year. The InvestingPro Tips also highlight that Inmune Bio is a niche player in its industry and holds more cash than debt, which could be a stabilizing factor for the company's balance sheet.


Despite the recent downturn in stock price, with a -9.0% return over the last week and -50.63% over the last six months, the CFO's investment suggests a belief in the company's resilience and future prospects. Moreover, the company's liquid assets exceed its short-term obligations, which may provide some cushion against market headwinds.


For investors looking for deeper insights, there are additional InvestingPro Tips available on Inmune Bio, Inc. These tips delve into the company's valuation multiples, trading patterns, and analyst expectations, all of which can be found at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com